Drug-induced gynecomastia: An evidence-based review

Expert Opinion on Drug Safety

Volumn 11, Issue 5, 2012, Pages 779-795

  Deepinder, Fnu ^a   Braunstein, Glenn D ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

adverse drug reactions; breast enlargement; drugs; gynecomastia; side effects

Indexed keywords

ANTIANDROGEN; ARIPIPRAZOLE; BICALUTAMIDE; CHORIONIC GONADOTROPIN; CIMETIDINE; CLOZAPINE; DUTASTERIDE; EFAVIRENZ; ESTROGEN; FINASTERIDE; FLUTAMIDE; GOSERELIN; KETOCONAZOLE; LAMIVUDINE; LEUPRORELIN; NIFEDIPINE; NILUTAMIDE; OLANZAPINE; OMEPRAZOLE; QUETIAPINE; RANITIDINE; RISPERIDONE; SAQUINAVIR; SPIRONOLACTONE; STAVUDINE; STEROID 5ALPHA REDUCTASE INHIBITOR; UNINDEXED DRUG; VERAPAMIL; ZIDOVUDINE; ZIPRASIDONE;

ALCOHOL ABUSE; ANDROGEN DEPRIVATION THERAPY; BIOTRANSFORMATION; CANCER RADIOTHERAPY; COCCIDIOIDOMYCOSIS; COMPETITIVE INHIBITION; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; DUODENUM ULCER; EMBASE; ERECTILE DYSFUNCTION; ESTRADIOL BLOOD LEVEL; ESTROGEN SYNTHESIS; EVIDENCE BASED MEDICINE; GYNECOMASTIA; HEART FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPROLACTINEMIA; HYPOGONADISM; MASTALGIA; MEDLINE; METHADONE TREATMENT; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROLACTIN BLOOD LEVEL; PROSTATE CANCER; RATING SCALE; REVIEW; SYSTEMATIC REVIEW; TESTOSTERONE BLOOD LEVEL;

14-ALPHA DEMETHYLASE INHIBITORS; ANDROGEN RECEPTOR ANTAGONISTS; EVIDENCE-BASED MEDICINE; GYNECOMASTIA; HUMANS; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PHARMACOVIGILANCE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 84865515699     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.712109     Document Type: Review

References (158)

1. Braunstein GD. Clinical practice. Gynecomastia N Engl J Med 2007;357(12):1229-37
2. Mathur R, Braunstein GD. Gynecomastia: pathomechanisms and treatment strategies. Horm Res 1997;48(3):95-102 (Pubitemid 27371019)
3. Braunstein GD. Gynecomastia. N Engl J Med 1993;328(7):490-5 (Pubitemid 23056441)
4. Thompson DF, Carter JR. Drug-induced gynecomastia. Pharmacotherapy 1993;13(1):37-45 (Pubitemid 23045282)
5. Eckman A, Dobs A. Drug-induced gynecomastia. Expert Opin Drug Saf 2008;7(6):691-702
6. Hill AB. The environment and disease: association or causation/? Proc R Soc Med 1965;58:295-300
7. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews - NCBI Bookshelf [Internet]. Available from: http://www.ncbi.nlm.nih.gov.mlprox.csmc.edu/books/NBK43437/ [Cited 15 Dec 2011]
8. Guirguis-Blake J, Calonge N, Miller T, et al. Current processes of the U.S. Preventive Services Task Force: refining evidence-based recommendation development. Ann Intern Med 2007;147(2):117-22 (Pubitemid 351664614)
9. Huffman DH, Kampmann JP, Hignite CE, et al. Gynecomastia induced in normal males by spironolactone. Clin Pharmacol Ther 1978;24(4):465-73 (Pubitemid 9059911)
10. Caminos-Torres R, Ma L, Snyder PJ. Gynecomastia and semen abnormalities induced by spironolactone in normal men. J Clin Endocrinol Metab 1977;45(2):255-60 (Pubitemid 8162811)
11. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341(10):709-17 (Pubitemid 29407370)
12. Rose LI, Underwood RH, Newmark SR, et al. Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med 1977;87(4):398-403
13. Spence RW, Celestin LR. Gynaecomastia associated with cimetidine. Gut 1979;20(2):154-7 (Pubitemid 9126892)
14. Jensen RT, Collen MJ, McArthur KE, et al. Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states. Am J Med 1984;77(5B):90-105 (Pubitemid 15175991)
15. García Rodríguez LA, Jick H. Risk of gynaecomastia associated with cimetidine, omeprazole, and other antiulcer drugs. BMJ 1994;308(6927):503-6
16. Funder JW, Mercer JE. Cimetidine, a histamine H2 receptor antagonist, occupies androgen receptors. J Clin Endocrinol Metab 1979;48(2):189-91 (Pubitemid 9122225)
17. Galbraith RA, Michnovicz JJ. The effects of cimetidine on the oxidative metabolism of estradiol. N Engl J Med 1989;3321(5):269-74 (Pubitemid 19193800)
18. Lardinois CK, Mazzaferri EL. Cimetidine blocks testosterone synthesis. Arch Intern Med 1985;145(5):920-2 (Pubitemid 15033262)
19. DeFelice R, Johnson DG, Galgiani JN. Gynecomastia with ketoconazole. Antimicrob Agents Chemother 1981;19(6):1073-4 (Pubitemid 11035898)
20. Sugar AM, Alsip SG, Galgiani JN, et al. Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother 1987;31(12):1874-8 (Pubitemid 18009552)
21. Pont A, Graybill JR, Craven PC, et al. High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med 1984;144(11):2150-3 (Pubitemid 15215501)
22. Pont A, Williams PL, Azhar S, et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med 1982;142(12):2137-40 (Pubitemid 12007067)
23. Pont A, Goldman ES, Sugar AM, et al. Ketoconazole-induced increase in estradiol-testosterone ratio. Probable explanation for gynecomastia. Arch Intern Med 1985;Aug145(8): 1429-31 (Pubitemid 15049798)
24. Grosso DS, Boyden TW, Pamenter RW, et al. Ketoconazole inhibition of testicular secretion of testosterone and displacement of steroid hormones from serum transport proteins. Antimicrob Agents Chemother 1983;23(2):207-12 (Pubitemid 13137524)
25. Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007;146(2):104-15 (Pubitemid 351640014)
26. Rudman D, Feller AG, Cohn L, et al. Effects of human growth hormone on body composition in elderly men. Horm Res 1991;36(Suppl 1):73-81
27. Sullivan DH, Carter WJ, Warr WR, et al. Side effects resulting from the use of growth hormone and insulin-like growth factor-I as combined therapy to frail elderly patients. J. Gerontol. A Biol Sci Med Sci 1998;53(3):M183-7 (Pubitemid 28232599)
28. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990;323(1):1-6 (Pubitemid 20209464)
29. Rosenbaum M, Gertner JM, Leibel RL. Effects of systemic growth hormone (GH) administration on regional adipose tissue distribution and metabolism in GH-deficient children. J Clin Endocrinol Metab 1989;69(6):1274-81 (Pubitemid 20010059)
30. Ng ST, Zhou J, Adesanya OO, et al. Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nat Med 1997;3(10):1141-4 (Pubitemid 27444458)
31. Burgués S, Calderón MD. Subcutaneous self-administration of highly purified follicle stimulating hormone and human chorionic gonadotropin for the treatment of male hypogonadotrophic hypogonadism. Spanish Collaborative Group on Male Hypogonadotropic Hypogonadism. Hum Reprod 1997;12(5):980-6 (Pubitemid 27271756)
32. Schopohl J, Mehltretter G, von Zumbusch R, et al. Comparison of gonadotropin-releasing hormone and gonadotropin therapy in male patients with idiopathic hypothalamic hypogonadism. Fertil Steril 1991;56(6):1143-50
33. Forest MG, Lecoq A, Saez JM. Kinetics of human chorionic gonadotropin-induced steroidogenic response of the human testis. II. Plasma 17 alpha-hydroxyprogesterone, delta4-androstenedione, estrone, and 17 beta-estradiol: evidence for the action of human chorionic gonadotropin on intermediate enzymes implicated in steroid biosynthesis. J Clin Endocrinol Metab 1979;49(2):284-91 (Pubitemid 9241275)
34. Harle LK, Maggio M, Shahani S, et al. Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin Adv Hematol Oncol 2006;4(9):687-96 (Pubitemid 44560316)
35. Thompson CA, Shanafelt TD, Loprinzi CL. Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist 2003;8(5):474-87 (Pubitemid 37238876)
36. Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003;61(2 Suppl 1):32-8 (Pubitemid 36349540)
37. Hedlund PO. Side effects of endocrine treatment and their mechanisms: castration, antiandrogens, and estrogens. Prostate 2000;10(Suppl):32-7
38. Mahler C, Denis L. Clinical profile of a new non-steroidal antiandrogen. J Steroid Biochem Mol Biol 1990;37(6):921-4
39. Wilton L, Pearce G, Edet E, et al. The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients. Br J Urol 1996;78(3):379-84
40. Green L, Wysowski DK, Fourcroy JL. Gynecomastia and breast cancer during finasteride therapy. N Engl J Med 1996;335(11):823 (Pubitemid 26296550)
41. Ferrando J, Grimalt R, Alsina M, et al. Unilateral gynecomastia induced by treatment with 1 mg of oral finasteride. Arch Dermatol 2002;138(4):543-4 (Pubitemid 34290044)
42. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349(3):215-24 (Pubitemid 36859473)
43. Debruyne F, Barkin J, van Erps P, et al. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004;46(4):488-94; discussion 495
44. Szarfman A, Tonning JM, Levine JG, et al. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 2006;26(6):748-58 (Pubitemid 43807626)
45. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64(20):2291-314 (Pubitemid 39388605)
46. Schlechte JA. Clinical practice. Prolactinoma N Engl J Med 2003;349(21):2035-41
47. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96(2):273-88
48. Sakiyama R, Quan M. Galactorrhea and hyperprolactinemia. Obstet Gynecol Surv 1983;38(12):689-700 (Pubitemid 15195088)
49. Carter JN, Tyson JE, Tolis G, et al. Prolactin-screening tumors and hypogonadism in 22 men. N Engl J Med 1978;299(16):847-52
50. Tanner LA, Bosco LA. Gynecomastia associated with calcium channel blocker therapy. Arch Intern Med 1988;148(2):379-80 (Pubitemid 18064814)
51. Boyd IW. Adverse drug reactions advisory committee. Gynaecomastia in association with calcium antagonists. Med J Aust 1994;161(5):328 (Pubitemid 24280609)
52. Veldhuis JD, Borges JL, Drake CR, et al. Divergent influences of the structurally dissimilar calcium entry blockers, diltiazem and verapamil, on thyrotropin-and gonadotropin-releasing hormone-stimulated anterior pituitary hormone secretion in man. J Clin Endocrinol Metab 1985;60(1):144-9 (Pubitemid 15194662)
53. Satoh T, Fujita KI, Munakata H, et al. Studies on the interactions between drugs and estrogen: analytical method for prediction system of gynecomastia induced by drugs on the inhibitory metabolism of estradiol using Escherichia coli coexpressing human CYP3A4 with human NADPH-cytochrome P450 reductase. Anal Biochem 2000;286(2):179-86
54. Satoh T, Munakata H, Fujita K, et al. Studies on the interactions between drug and estrogen. II. On the inhibitory effect of 29 drugs reported to induce gynecomastia on the oxidation of estradiol at C-2 or C-17. Biol Pharm Bull 2003;26(5):695-700 (Pubitemid 39663566)
55. Satoh T, Tomikawa Y, Takanashi K, et al. Studies on the interactions between drugs and estrogen. III. Inhibitory effects of 29 drugs reported to induce gynecomastia on the glucuronidation of estradiol. Biol Pharm Bull 2004;27(11):1844-9 (Pubitemid 41701616)
56. García Rodríguez LA, Jick H. Risk of gynaecomastia associated with cimetidine, omeprazole, and other antiulcer drugs. BMJ 1994;308(6927):503-6
57. Carvajal A, Macias D, Gutiérrez A, et al. Gynaecomastia associated with proton pump inhibitors: a case series from the Spanish Pharmacovigilance System. Drug Saf 2007;30(6):527-31 (Pubitemid 46873077)
58. Lindquist M, Edwards IR. Endocrine adverse effects of omeprazole. BMJ 1992;305(6851):451-2
59. Santucci L, Farroni F, Fiorucci S, et al. Gynecomastia during omeprazole therapy. N Engl J Med 1991;324(9):635
60. Piroth L, Grappin M, Petit JM, et al. Incidence of gynecomastia in men infected with HIV and treated with highly active antiretroviral therapy. Scand J Infect Dis 2001;33(7):559-60 (Pubitemid 32755356)
61. Peyriere H, Mauboussin JM, Rouanet I, et al. Report of gynecomastia in five male patients during antiretroviral therapy for HIV infection. AIDS 1999;13(15):2167-9 (Pubitemid 29509596)
62. Donovan B, Bodsworth NJ, Mulhall BP, et al. Gynaecomastia associated with saquinavir therapy. Int J STD AIDS 1999;10(1):49-50 (Pubitemid 29039160)
63. Rahim S, Ortiz O, Maslow M, et al. A case-control study of gynecomastia in HIV-1-infected patients receiving HAART. AIDS Read 2004; 14(1):23-4; 29-32, 35-40
64. Manfredi R, Calza L, Chiodo F. Another emerging event occurring during HIV infection treated with any antiretroviral therapy: frequency and role of gynecomastia. Infez Med 2004;12(1):51-9 (Pubitemid 38987191)
65. Caso JA, Prieto J de M, Casas E, et al. Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz. AIDS 2001;15(11):1447-8 (Pubitemid 32662300)
66. Qazi NA, Morlese JF, King DM, et al. Gynaecomastia without lipodystrophy in HIV-1-seropositive patients on efavirenz: an alternative hypothesis. AIDS 2002;16(3):506-7 (Pubitemid 34165393)
67. Evans DL, Pantanowitz L, Dezube BJ, et al. Breast enlargement in 13 men who were seropositive for human immunodeficiency virus. Clin Infect Dis 2002;35(9):1113-19 (Pubitemid 35239472)
68. Imami N, Antonopoulos C, Hardy GA, et al. Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy. AIDS Res Hum Retroviruses 1999;15(17):1499-508
69. Katano M, Matsuo T, Morisaki T, et al. Increased proliferation of a human breast carcinoma cell line by recombinant interleukin-2. Cancer Immunol Immunother 1994;39(3):161-6 (Pubitemid 24298389)
70. Singh A, Purohit A, Ghilchik MW, et al. The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2. Endocr Relat Cancer 1999;6(2):139-47 (Pubitemid 29260045)
71. Forest MG, Lecoq A, Saez JM. Kinetics of human chorionic gonadotropin-induced steroidogenic response of the human testis. II. Plasma 17 alpha-hydroxyprogesterone, delta4-androstenedione, estrone, and 17 beta-estradiol: evidence for the action of human chorionic gonadotropin on intermediate enzymes implicated in steroid biosynthesis. J Clin Endocrinol Metab 1979;49(2):284-91 (Pubitemid 9241275)
72. Trump DL, Anderson SA. Painful gynecomastia following cytotoxic therapy for testis cancer: a potentially favorable prognostic sign? J Clin Oncol 1983;1(7):416-20 (Pubitemid 13002958)
73. Tseng A Jr, Horning SJ, Freiha FS, et al. Gynecomastia in testicular cancer patients. Prognostic and therapeutic implications. Cancer 1985;56(10):2534-8 (Pubitemid 16202456)
74. Turner AR, Morrish DW, Berry J, et al. Gynecomastia after cytotoxic therapy for metastatic testicular cancer. Arch Intern Med 1982;142(5):896-7 (Pubitemid 12125520)
75. Schorer AE, Oken MM, Johnson GJ. Gynecomastia with nitrosourea therapy. Cancer Treat Rep 1978;62(4):574-6 (Pubitemid 8345582)
76. Large DM, Jones JM, Shalet SM, et al. Gynaecomastia complicating the treatment of myeloma. Br J Cancer 1983;48(1):69-74 (Pubitemid 13067947)
77. Sherins RJ, Olweny CL, Ziegler JL. Gynecomastia and gonadal dysfunction in adolescent boys treated with combination chemotherapy for Hodgkin's disease. N Engl J Med 1978;299(1):12-16 (Pubitemid 8387365)
78. Glass AR, Berenberg J. Gynecomastia after chemotherapy for lymphoma. Arch Intern Med 1979;139(9):1048-9 (Pubitemid 10147657)
79. Saeter G, Fosså SD, Norman N. Gynaecomastia following cytotoxic therapy for testicular cancer. Br J Urol 1987;59(4):348-52 (Pubitemid 17053821)
80. Schilsky RL, Lewis BJ, Sherins RJ, et al. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med 1980;93(1):109-14 (Pubitemid 10072013)
81. Evans NA. Gym and tonic: a profile of 100 male steroid users. Br J Sports Med 1997;31(1):54-8 (Pubitemid 27110622)
82. Korkia P, Stimson GV. Indications of prevalence, practice and effects of anabolic steroid use in Great Britain. Int J Sports Med 1997;18(7):557-62 (Pubitemid 27496911)
83. Pope HG Jr, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch Gen Psychiatry 1994;51(5):375-82 (Pubitemid 24176815)
84. Brown GA, Vukovich MD, Martini ER, et al. Endocrine responses to chronic androstenedione intake in 30-to 56-year-old men. J Clin Endocrinol Metab 2000;85(11):4074-80 (Pubitemid 32055355)
85. Leder BZ, Longcope C, Catlin DH, et al. Oral androstenedione administration and serum testosterone concentrations in young men. JAMA 2000;283(6):779-82 (Pubitemid 30084618)
86. Calzada L, Torres-Calleja J, Martinez JM, et al. Measurement of androgen and estrogen receptors in breast tissue from subjects with anabolic steroid-dependent gynecomastia. Life Sci 2001;69(13):1465-9 (Pubitemid 32786720)
87. Boyden TW, Pamenter RW. Effects of ethanol on the male hypothalamic-pituitary-gonadal axis. Endocr Rev 1983;4(4):389-95
88. Adler RA. Clinical review 33: clinically important effects of alcohol on endocrine function. J Clin Endocrinol Metab 1992;74(5):957-60
89. Van Thiel DH, Cobb CF, Herman GB, et al. An examination of various mechanisms for ethanol-induced testicular injury: studies utilizing the isolated perfused rat testes. Endocrinology 1981;109(6):2009-15 (Pubitemid 12252327)
90. Gavaler JS. Alcoholic beverages as a source of estrogens. Alcohol Health Res World 1998;22(3):220-7 (Pubitemid 128684665)
91. Cicero TJ, Bell RD, Wiest WG, et al. Function of the male sex organs in heroin and methadone users. N Engl J Med 1975;292(17):882-7
92. Mendelson JH, Meyer RE, Ellingboe J, et al. Effects of heroin and methadone on plasma cortisol and testosterone. J Pharmacol Exp Ther 1975;195(2):296-302
93. Thomas BL. Letter: methadone-associated gynecomastia. N Engl J Med 1976;294(3):169
94. de la Rosa RE, Hennessey JV. Hypogonadism and methadone: hypothalamic hypogonadism after long-term use of high-dose methadone. Endocr Pract 1996;2(1):4-7
95. Bliesener N, Albrecht S, Schwager A, et al. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab 2005;90(1):203-6 (Pubitemid 40116658)
96. Margolis IB, Gross CG. Gynecomastia during phenothiazine therapy. JAMA 1967;199(12):942-4
97. Shader RI, DiMascio A. Endocrine effects of psychotropic drugs. 1. Galactorrhea and gynecomastia. Conn Med 1968;32(2):106-8
98. Kaneda Y, Fujii A. Gynecomastia with sulpiride. J Clin Pharm Ther 2002;27(1):75-7 (Pubitemid 34175437)
99. Storch DD. Gynecomastia with antipsychotics. J Am Acad Child Adolesc Psychiatry 1997;36(2):161-2
100. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64(20):2291-314 (Pubitemid 39388605)
101. Boulenger A, Viseux V, Plantin-Eon I, et al. Gynaecomastia following treatment by fluoxetine. J Eur Acad Dermatol Venereol 2003;17(1):109
102. Sahin M, Yilmaz H, Guvener ND. A possible case of gynecomastia with fluoxetine. Ann Pharmacother 2005;39(7-8):1369
103. Benazzi F. Gynecomastia with risperidone-fluoxetine combination. Pharmacopsychiatry 1999;32(1):41 (Pubitemid 29077264)
104. Damsa C, Sterck R, Schulz P. Case of gynecomastia during paroxetine therapy. J Clin Psychiatry 2003;64(8):971
105. Karakurt F, Kargili A, Uz B, et al. Venlafaxine-induced gynecomastia in a young patient: a case report. Clin Neuropharmacol 2009;32(1):51-2
106. Jelenkovic AV, Macukanovic-Golubovic LD. Diazepam-associated gynecomastia. Ann Pharmacother 2005;39(1):201
107. Bergman D, Futterweit W, Segal R, et al. Increased oestradiol in diazepam related gynaecomastia. Lancet 1981;2(8257):1225-6 (Pubitemid 12228363)
108. Monson JP, Scott DF. Gynaecomastia induced by phenytoin in men with epilepsy. Br Med J (Clin Res Ed) 1987;294(6572):612 (Pubitemid 17028147)
109. Ikeda A, Hattori H, Odani A, et al. Gynaecomastia in association with phenytoin and zonisamide in a patient having a CYP2C subfamily mutation. J Neurol Neurosurg Psychiatr 1998;65(5):803-4 (Pubitemid 28486677)
110. Málaga I, Sanmarti FX. Two cases of painful gynecomastia and lower extremity pain in association with pregabalin therapy. Epilepsia 2006;47(9):1576-9 (Pubitemid 44393873)
111. Zylicz Z. Painful gynecomastia: an unusual toxicity of gabapentin? J Pain Symptom Manage 2000;20(1):2-3 (Pubitemid 30628575)
112. Cornes PG, Hole AC. Amlodipine gynaecomastia. Breast 2001;10(6):544-5 (Pubitemid 33150373)
113. Zochling J, Large G, Fassett R. Gynaecomastia and amlodipine. Med J Aust 1994;160(12):807
114. Markusse HM, Meyboom RH. Gynaecomastia associated with captopril. Br Med J (Clin Res Ed) 1988;296(6631):1262-3
115. Nakamura Y, Yoshimoto K, Saima S. Gynaecomastia induced by angiotensin converting enzyme inhibitor. BMJ 1990;300(6723):541 (Pubitemid 20085555)
116. Antonelli D, Luboshitzky R, Gelbendorf A. Amiodarone-induced gynecomastia. N Engl J Med 1986;315(24):1553 (Pubitemid 17052163)
117. Lewinn EB. Gynecomastia during digitalis therapy; report of eight additional cases with liver-function studies. N Engl J. Med 1953;248(8):316-20
118. Dall JL. Digitalis Intoxication in elderly patients. Lancet 1965;1(7378):194-5
119. Singer EP. Gynecomastia following digitalis administration. J Med Soc N J 1967;64(10):557-9
120. Stoffer SS, Hynes KM, Jiang NS, et al. Digoxin and abnormal serum hormone levels. JAMA 1973;225(13):1643-4
121. Burckhardt D, Vera CA, LaDue JS. Effect of digitalis on urinary pituitary gonadotropin excretion. A study in postmenopausal women. Ann Intern Med 1968;68(5):1069-71
122. Aerts J, Karmochkine M, Raguin G. [Gynecomastia due to pravastatin]. Presse Med 1999;28(15):787
123. Hammons KB, Edwards RF, Rice WY. Golf-inhibiting gynecomastia associated with atorvastatin therapy. Pharmacotherapy 2006;26(8):1165-8 (Pubitemid 44167824)
124. Oteri A, Catania MA, Travaglini R, et al. Gynecomastia possibly induced by rosuvastatin. Pharmacotherapy 2008;28(4):549-51 (Pubitemid 351466467)
125. Gardette V, Vezzosi D, Maiza J-C, et al. Gynecomastia associated with fenofibrate. Ann Pharmacother 2007;41(3):508-10
126. Tosi S, Cagnoli M. Painful gynecomastia with ranitidine. Lancet 1982;2(8290):160
127. Madani S, Tolia V. Gynecomastia with metoclopramide use in pediatric patients. J Clin Gastroenterol 1997;24(2):79-81 (Pubitemid 27142927)
128. Keating JP, Rees M. Gynaecomastia after long-term administration of domperidone. Postgrad Med J 1991;67(786):401-2
129. van der Steen M, Du Caju MV, Van Acker KJ. Gynecomastia in a male infant given domperidone. Lancet 1982;2(8303):884-5 (Pubitemid 12018571)
130. Soykan I, Sarosiek I, McCallum RW. The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. Am J Gastroenterol 1997;92(6):976-80 (Pubitemid 27237588)
131. Garg R, Vaibhav Mehra S, et al. Isoniazid induced gynaecomastia: a case report. Indian J Tuberc 2009;56(1):51-4
132. Khanna P, Panjabi C, Maurya V, et al. Isoniazid associated, painful, bilateral gynaecomastia. Indian J Chest Dis Allied Sci 2003;45(4):277-9
133. Dixit R, Sharma S, Nawal CL. Gynaecomastia during antituberculosis chemotherapy with isoniazid. J Assoc Phys India 2008;56:390-1
134. Morrone N, Morrone Junior N, Braz AG, et al. Gynecomastia: a rare adverse effect of isoniazid. J Bras Pneumol 2008;34(11):978-81
135. Davies JP, Price-Thomas JM. Gynaecomastia in association with minocycline. Br J Clin Pract 1995;49(4):179
136. Fagan TC, Johnson DG, Grosso DS. Metronidazole-induced gynecomastia. JAMA 1985;254(22):3217 (Pubitemid 16206974)
137. Del Paine DW, Leek JC, Jakle C, et al. Gynecomastia associated with low dose methotrexate therapy. Arthritis Rheum 1983;26(5):691-2 (Pubitemid 13090028)
138. Thomas E, Leroux JL, Blotman F. Gynecomastia in patients with rheumatoid arthritis treated with methotrexate. J Rheumatol 1994;21(9):1777-8 (Pubitemid 24285508)
139. Finger DR, Klipple GL. Gynecomastia following low dose methotrexate therapy for rheumatoid arthritis. J Rheumatol 1995;22(4):796-7
140. Aguirre MA, Vélez A, Romero M, et al. Gynecomastia and sexual impotence associated with methotrexate treatment. J. Rheumatol 2002;29(8):1793-4 (Pubitemid 34831258)
141. Pandhi D, Gupta R, Singal A. Gynaecomastia with oligospermia: an unusual complication of low-dose methotrexate for pustular psoriasis. Clin Exp Dermatol 2006;31(1):138-40
142. Pulik M, Genet P, Lionnet F, et al. Thalidomide-associated gynecomasty in a patient with multiple myeloma. Am J Hematol 2002;70(3):265 (Pubitemid 34680694)
143. Iaria G, Urbani L, Catalano G, et al. Switch to tacrolimus for cyclosporine-induced gynecomastia in liver transplant recipients. Transplant Proc 2005;37(6):2632-3 (Pubitemid 41354695)
144. Harmon J, Aliapoulios MA. Gynecomastia in marihuana users. N Engl J Med 1972;287(18):936
145. Olusi SO. Hyperprolactinaemia in patients with suspected cannabis-induced gynaecomastia. Lancet 1980;1(8162):255 (Pubitemid 10207675)
146. Allen RC, Wallace AM, Royce M. Marinol-induced gynecomastia: a case report. Am J Med 2007;120(10):e1 (Pubitemid 47454725)
147. Sauer MA, Rifka SM, Hawks RL, et al. Marijuana: interaction with the estrogen receptor. J Pharmacol Exp Ther 1983;224(2):404-7 (Pubitemid 13139098)
148. Tooley PH, Lack C. Gynecomastia during treatment with amphetamine. Lancet 1949;1(6555):650
149. Dardick KR. Gynecomastia associated with theophylline. J Fam Pract 1984;18(1):141-2 (Pubitemid 14219533)
150. Mendhekar DN. Clonidine-induced gynecomastia and hyperprolactinemia in a 6-year-old child. J Clin Psychiatry 2005;66(12):1616-17
151. Reid DM, Martynoga AG, Nuki G. Reversible gynaecomastia associated with D-penicillamine in a man with rheumatoid arthritis. Br Med J (Clin Res Ed) 1982;285(6348):1083-4 (Pubitemid 12029695)
152. Roberts HJ. Vitamin E and gynecomastia. Hosp Pract (Off. Ed.) 1994;29(1):12 (Pubitemid 24036409)
153. De Bleecker JL, Lamont BH, Verstraete AG, et al. Melatonin and painful gynecomastia. Neurology 1999;53(2):435-6 (Pubitemid 29344382)
154. Bridgman JF, Buckler JM. Letter: drug-induced gynaecomastia. Br Med J 1974;3(5929):520-1
155. Jameel JKA, Kneeshaw PJ, Rao VSR, et al. Gynaecomastia and the plant product "Tribulis terrestris". Breast 2004;13(5):428-30 (Pubitemid 39549795)
156. Sahin M, Yilmaz H, Gursoy A, et al. Gynaecomastia in a man and hyperoestrogenism in a woman due to ingestion of nettle (Urtica dioica). NZ Med J 2007;120(1265):U2803
157. Henley DV, Lipson N, Korach KS, et a Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Me 2007;356(5):479-85 (Pubitemid 46193075)
158. Martinez J, Lewi JE. An unusual case of gynecomastia associated with soy product consumption. Endocr Pract 2008;14(4):415-18